Find recruiting clinical trials for brain tumours in the UK — including tumour-treating fields for glioblastoma, IDH inhibitor trials for glioma, immunotherapy vaccines, and novel targeted therapies for paediatric brain tumours. See your treatment pathway and where trials fit in.
Free to use — Live data from ClinicalTrials.gov — Updated hourly
Answer a few questions about your condition and we'll match you to the most relevant clinical trials.
See where clinical trials fit into your treatment journey
Slow-growing tumours — often IDH-mutant, 1p/19q codeleted
Standard: Maximal safe resection, radiotherapy, chemotherapy (PCV or temozolomide) for high-risk, observation for low-risk
Aggressive, rapidly growing brain tumours (WHO Grade 4)
Standard: Stupp protocol — maximal safe resection, radiotherapy + temozolomide, then adjuvant temozolomide
Mostly benign — but atypical or anaplastic subtypes can recur
Standard: Surgical resection (Simpson grade), radiotherapy for residual or high-grade, SRS for small or inaccessible
Medulloblastoma, ependymoma, DIPG, craniopharyngioma
Standard: Multi-modal risk-stratified protocols per CCLG; chemotherapy, radiotherapy, with molecular subtype-directed adjustments
Vorasidenib and olutasidenib target mutant IDH1/2 — a defining mutation in most low-grade gliomas. These oral agents can cross the blood-brain barrier and are being tested as first-line therapy to delay chemotherapy and radiotherapy.
Optune delivers low-intensity, alternating electric fields through transducer arrays on the scalp, disrupting mitosis in glioblastoma cells. UK trials are testing TTFields in newly diagnosed GBM and alongside novel systemic therapies.
DCVax-L (dendritic cell vaccine), checkpoint inhibitors for the small subset of hypermutated glioblastomas, and CAR-T cell therapy targeting IL-13Rα2 or EGFRvIII — all being studied in UK neuro-oncology centres.
Novel approaches to deliver drugs across the blood-brain barrier — including focused ultrasound with microbubbles, convection-enhanced delivery, and nanoparticle formulations of standard chemotherapy agents.
Loading trials from ClinicalTrials.gov...
Yes. There are active UK trials for glioblastoma testing tumour-treating fields, novel chemotherapy combinations, immunotherapy vaccines (DCVax), and targeted agents based on MGMT methylation and IDH mutation status.
Yes. Trials exist for meningioma, low-grade glioma, and pituitary tumours — including novel medical therapies, radiosurgery protocols, and observation-based studies to determine optimal timing of intervention.
Yes. Tumour-treating fields (Optune) are available through UK trials for newly diagnosed and recurrent glioblastoma. The therapy uses low-intensity electric fields to disrupt cancer cell division.
Yes. The Children's Cancer and Leukaemia Group (CCLG) coordinates paediatric brain tumour trials across the UK, including medulloblastoma, ependymoma, and DIPG (diffuse intrinsic pontine glioma).
Use our search above to find trials matching your condition and location. Review eligibility criteria carefully.
Talk to your GP or neuro-oncologist about any trials you are interested in. They can help determine if a trial is appropriate for you.
Reach out to the trial team directly using the contact information on the ClinicalTrials.gov listing.
If you meet the criteria and decide to participate, you will go through informed consent and begin the trial process.